Not all patients with CLL need therapy. In spite of all latest advancements, the iwCLL still endorses watchful observation for sufferers with asymptomatic sickness.86 This advice is predicated on not less than two randomized trials evaluating observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104 B